Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04374149 · ClinicalTrials.gov registry record · Phase 2
Therapeutic Plasma Exchange Alone or in Combination With Ruxolitinib in COVID-19 Associated CRS
A Phase 2 study, sponsored by Prisma Health-Upstate.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT04374149 is a Phase 2 study that has completed, run by Prisma Health-Upstate. The registered enrollment target is 20 participants.
The verdict
NCT04374149, a Phase 2 study, has completed, sponsored by Prisma Health-Upstate.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
This protocol will evaluate the efficacy of Therapeutic Plasma Exchange (TPE) alone or in combination with ruxolitinib in COVID positive patients with PENN grade 2, 3, 4 cytokine release syndrome (CRS). It is hypothesized that dual intervention of acute apheretic depletion of cytokines and concomitant suppression of production will produce superior amelioration of the cytokine load and to help to prevent cytokine load rebound. This protocol is envisioned as a pilot study (n=20) for hypothesis generation for future investigation.
Interventions
- DRUG Ruxolitinib
- PROCEDURE Therapeutic Plasma Exchange
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2020-04-30 |
| Est. Completion | 2020-12-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04374149
The ClinicalTrials.gov registry entry for NCT04374149 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Prisma Health-Upstate, which has 67 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ruxolitinib is the first listed.
NCT04374149 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04374149 about?
NCT04374149 is a clinical study titled "Therapeutic Plasma Exchange Alone or in Combination With Ruxolitinib in COVID-19 Associated CRS". This protocol will evaluate the efficacy of Therapeutic Plasma Exchange (TPE) alone or in combination with ruxolitinib in COVID positive patients with PENN grade 2, 3, 4 cytokine release syndrome (CRS). It is hypothesized that dual intervention of acute apheretic depletion of cytokines and concomita...
What is the current status of trial NCT04374149?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2020-04-30. Estimated completion is 2020-12-01.
What interventions are being tested in trial NCT04374149?
The interventions under investigation include: Ruxolitinib (DRUG), Therapeutic Plasma Exchange (PROCEDURE).
Who is sponsoring clinical trial NCT04374149?
This trial is sponsored by Prisma Health-Upstate, which has 67 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.